期刊文献+

低分割三维适形放射结合介入治疗肝细胞癌伴门静脉癌栓的疗效 被引量:18

Efficacy of 3-Dimensional Conformal Hypofractionated Single High dose Radiotherapy Combined with Transcatheter Arterial Chemoembolization for Portal Vein Tumor Thrombus in Patients with Hepatocellular Carcinoma
在线阅读 下载PDF
导出
摘要 背景与目的肝细胞癌常伴有门静脉癌栓且预后极差,有学者用三维适形放射治疗常规剂量分割模式进行治疗取得了较好的疗效。本研究的目的是评价低分割三维适形放射治疗(3-dimensionalconformalradiationtherapy,3DCRT)结合经皮肝动脉化疗栓塞(transcatheterarterialchemoembolization,TACE)治疗肝细胞癌(hepatocellularcarcinoma,HCC)伴门静脉癌栓(portalveintumorthrombus,PVTT)的疗效。方法对35例不能手术切除的HCC伴PVTT患者,采用低分割3DCRT结合TACE进行治疗,根据肿瘤体积大小,放射采用每次4~8Gy,3次/周;48~60Gy,8~12分次,3.0~3.5周完成。观察近期疗效,用Kaplan-Meier法进行生存分析,采用Cox比例风险模型作多因素分析。结果肿瘤缓解率为71.4%,1、2、3年累积生存率分别是59.3%、31.6%、26.6%,中位生存期11个月。多因素分析显示Child分级是影响预后的主要因素(P<0.05)。放射性肝炎和胃肠道出血是最常见的并发症。结论大分割3DCRT结合TACE治疗HCC伴PVTT有较好的疗效。肝功能Child分级与患者的预后有密切关系。 BACKGROUND & OBJECTIVE: Hepatocellular carcinoma (HCC) often results in portal vein tumor thrombus (PVTT), and the prognosis of the patients is extremely poor. It has been reported that some oversea scholars achieved fine therapeutic effects in treatment of this disease by 3 dimensional conformal radiation therapy (3DCRT) in fractionated conventional dose. The aim of this study was to evaluate the efficacy of 3 dimensional conformal hypofractionated single high dose radiotherapy combined with transcatheter arterial chemoembolization (TACE) for portal vein tumor thrombus in patients with hepatocellular carcinoma. METHODS: From May 1998 to December 2000, 35 patients with unresectable HCC complicated with PVTT were treated with 3 dimensional conformal hypofractionated single high dose radiotherapy and TACE. According to the volume of the tumors, radiotherapy was performed at an exposure of 4-8 Gy/time, 3 times/week, 48-60 Gy, 8 12 times, 3.0 3.5 weeks. The objective responses were analyzed and the survival rates were assessed from the date of the beginning of treatment using the Kaplan Meier method. The Cox proportional hazards model was used to analyze the prognostic factors. RESULTS: The objective response was 71.4%. The overall survival rates were 59.3%, 31.6%, and 26.6% at 1, 2, 3 years, respectively, with a median survival time of 11 months. Cox proportional hazards model analysis showed that Child Pugh class was the most important prognostic factors for the survival probability of the patients. Radiation induced liver disease (RILD) and gastrointestinal bleeding were the most common treatment related complications. CONCLUSIONS: 3 Dimensional conformal hypofractionated single high dose radiotherapy combined with TACE is an effective and feasible approach to treat PVTT in unresectabe HCC patients. Child Pugh class was identified as a predictor for PVTT in unresectabe HCC patients.
出处 《癌症》 SCIE CAS CSCD 北大核心 2004年第7期825-828,共4页 Chinese Journal of Cancer
基金 广东省自然科学基金重点项目(013056)~~
关键词 肝肿瘤 门静脉癌栓 放射疗法 治疗性栓塞 Hepatic Neoplasm Portal thrombus Radiotherapy Therapeutic embolization
  • 相关文献

参考文献2

二级参考文献11

  • 1Mario Pirisi,Claudio Avellini,Carlo Fabris,Cathryn Scott,Paola Bardus,Giorgio Soardo,Carlo A. Beltrami,Ettore Bartoli.Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study[J].Journal of Cancer Research and Clinical Oncology.1998(7)
  • 2Masao Mitsunobu,Akihiro Toyosaka,Takeshi Oriyama,Eizo Okamoto,Norio Nakao.Intrahepatic metastases in hepatocellular carcinoma: the role of the portal vein as an efferent vessel[J].Clinical & Experimental Metastasis.1996(6)
  • 3Tetsuya Katsumori M.D.,Masato Fujita,Takeshi Takahashi,Osamu Satoh,Shigeki Ichijima,Toshiyuki Nakamura,Hiroyuki Morishita,Kohji Ohno,Yasuhiko Nakano,Tomoho Maeda.Effective segmental chemoembolization of advanced hepatocellular carcinoma with tumor thrombus in the portal vein[J].CardioVascular and Interventional Radiology.1995(4)
  • 4Shinn-Cherng Chen,Shi-Long Lian,Wen-Yu Chang.The effect of external radiotherapy in treatment of portal vein invasion in hepatocellular carcinoma[J].Cancer Chemotherapy and Pharmacology.1994(1)
  • 5Yoshio Yamaoka M.D.,Kaoru Kumada M.D.,Keiichi Ino M.D.,Takashi Takayasu M.D.,Yasuyuki Shimahara M.D.,Keiichiro Mori M.D.,Akira Tanaka M.D.,Taisuke Morimoto M.D.,Yoshiro Taki M.D.,Masanobu Washida M.D.,Dai Manaka M.D.,Michihiro Hayashi M.D.,Takusi Fujita M.D.,Kazue Ozawa M.D.Liver resection for hepatocellular carcinoma (HCC) with direct removal of tumor thrombi in the main portal vein[J].World Journal of Surgery.1992(6)
  • 6Chung JW,Park JH,Hen JK,Choi BI,Hen MC.Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization[].American Journal of Roentgenology.1995
  • 7Engelberg H.Actions of heparin that may affect the malignant process[].Cancer.1999
  • 8Gurgey A,Buyukpamukcu M,Baskut C,Yalcin B,Gogus S.Portal vein thrombosis in association with factor V Leiden mutation in a patient with hepatocellular carcinoma[].Medical and Pediatric Oncology.1997
  • 9Ando E,Yamashita F,Tanaka M,Tanikawa K.A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein[].Cancer.1997
  • 10Livraghi T,Grigioni W,Mazziotti A,Sangalli G,Vettori C.Percuteneous alcohol injection of portal thrombosis in hepatocellular carcinoma: a new possible treatment[].TUMORI.1990

共引文献1092

同被引文献89

引证文献18

二级引证文献105

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部